Quantcast
Last updated on April 18, 2014 at 10:16 EDT

Latest Medical genetics Stories

2014-01-20 23:04:09

GIA announces the release of a trend report on Designer Babies. The concept of Designer Babies is gaining in popularity driven by developments in genetic engineering that help scientists to screen embryos for genetic disorders to artificially make babies with desired personal and genetic traits. San Jose, California (PRWEB) January 20, 2014 Follow us on LinkedIn – Designer babies are defined as babies with artificial genetic makeup selected through a combination of genetic engineering...

Eye Gene Therapy
2014-01-16 09:44:41

Brett Smith for redOrbit.com - Your Universe Online A newly developed genetic therapy for treating a type of inherited blindness called choroideremia is showing some promise and allowing patients to see incrementally more than they had before the treatment, according to a new report in The Lancet. Six patients in the study had one eye treated with the gene therapy in operations at the Oxford Eye Hospital in the United Kingdom. After six months, the treated eye showed improved vision in...

2014-01-14 23:04:55

Houston area pharmacogenomics lab utilizes regional health information network to ensure broad provider access to genetic profiles. Houston, Texas (PRWEB) January 14, 2014 Healthconnect announced today that it has become one of the first health information networks in the country to sign-on a pharmacogenomics lab, Companion Dx, for the broad dissemination of genetic test results. By making archived records available through Healthconnect, Companion Dx can ensure that genetic information...

2014-01-14 12:26:51

Spark CEO provides corporate updates at the J.P. Morgan Conference SAN FRANCISCO, Jan. 14, 2014 /PRNewswire/ -- Spark Therapeutics, a late-stage gene therapy company, has reached its patient recruitment goal for its most advanced clinical program, a Phase 3 study for inherited retinal dystrophies caused by mutations in the RPE65 gene. Spark's CEO, Jeffrey D. Marrazzo, is presenting this and other corporate updates today, at the 32nd Annual J.P. Morgan Healthcare Conference in San Francisco....

2014-01-09 08:29:33

Joseph La Barge and Carol Greve-Philips expand business operations PHILADELPHIA, Jan. 9, 2014 /PRNewswire/ -- Spark Therapeutics, a late-stage, fully integrated company developing gene-based medicines for a wide range of debilitating diseases, announced today that it has expanded its leadership team through the addition of two industry veterans, Joseph La Barge and Carol Greve-Philips, who have extensive track records successfully growing biotech businesses. Joseph La Barge has...

2014-01-06 12:24:34

Clinical Chemistry Women's Health Issue Explores the Ethics of Genetic Testing for Reproduction WASHINGTON, Jan. 6, 2014 /PRNewswire-USNewswire/ -- Jodi Picoult's 2004 novel My Sister's Keeper became a bestseller by exploring the fate of a young girl who is genetically engineered to be a donor match for her cancer-stricken older sister. My Sister's Keeper is fiction, but it is based on the reality of preimplantation genetic diagnosis (PGD). A new Q&A in the "Advancing Women's...

2013-12-30 12:21:41

BETHESDA, Md., Dec. 30, 2013 /PRNewswire-USNewswire/ -- Since the National Human Genome Project first revealed the human genome sequence, work began in earnest on how to apply this remarkable new knowledge to patient care. In an important step in helping current physicians and other healthcare professionals who are not board-certified geneticists to understand genomics in the clinical setting, the American College of Medical Genetics and Genomics (ACMG) has just created a series of...

2013-12-23 12:24:13

PLYMOUTH, Mich., Dec. 23, 2013 /PRNewswire-USNewswire/ -- After nearly a decade in the city of Detroit, Genesis Genetics has moved its corporate headquarters to Plymouth, Michigan. Tony Gordon Ph.D., Genesis Genetics Managing Director, leads the team of scientists, genetic counselors and case coordinators. In the United States, Genesis Genetics focuses its science on two important fertility technologies: Preimplantation Genetic Screening (PGS) and Preimplantation Genetic Diagnosis...

2013-12-20 08:26:00

PHILADELPHIA, Dec. 20, 2013 /PRNewswire/ -- Spark Therapeutics, a fully integrated, late-stage gene therapy company, announced today that President and Chief Executive Officer Jeffrey D. Marrazzo will present a company overview at the 32(nd) Annual J.P. Morgan Healthcare Conference. Marrazzo's presentation will highlight the company's progress in developing potentially curative, one-time gene therapies for the treatment of inherited blindness and hemophilia, and provide an overview of...

2013-12-18 15:08:14

Research team identified Neurexin2 as a novel target for potential therapy of neurodegeneration in Spinal Muscular Atrophy patients A recent study led by scientists from the National University of Singapore (NUS) opens a possible new route for treatment of Spinal Muscular Atrophy (SMA), a devastating disease that is the most common genetic cause of infant death and also affects young adults. As there is currently no known cure for SMA, the new discovery gives a strong boost to the fight...